Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 4—April 2014

Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009

Russell S. Barlow, Emilio E. DeBessComments to Author , Kevin L. Winthrop, Jodi A. Lapidus, Robert Vega, and Paul R. Cieslak
Author affiliations: Oregon Health Authority, Portland, Oregon USA (R.S. Barlow, E.E. DeBess, P.R. Cieslak); Oregon Health and Science University, Portland (R.S. Barlow, K.L. Winthrop, J.A. Lapidus); Oregon State Public Health Lab, Hillsboro, Oregon, USA (R. Vega)

Main Article

Table 2

Serotype-adjusted odds of salmonellosis with resistance to specific antimicrobial drugs per year, Oregon, USA, 2004–2009*

Variable Odds ratio (95% CI)†
Ampicillin 1.1 (1.0–1.1)
Cephalosporins 1.2 (1.0–1.6)
Gentamicin 1.0 (0.9–1.2)
Quinolones‡ 1.3 (1.1–1.5)
Trimethoprim/sulfamethoxazole 1.3 (1.1–1.5)
CIR 1.1 (1.0–1.2)§

*Multiple logistic regression analysis of 2,127 isolates. Boldface indicates statistical significance at p<0.05.
†Serotype adjusted; increased odds of resistance per year, 2004–2009.
‡Resistant to naladixic acid or ciprofloxacin.

Main Article

Page created: March 18, 2014
Page updated: March 18, 2014
Page reviewed: March 18, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.